Titan Bio-Tech

₹499.9 -7.4 | 1.5%

WEBSITE BSE:524717 NSE : TITAN BIOTEC 18 May, 12:50

Market Cap ₹413 Cr.

Stock P/E 16.7

P/B 3.2

Current Price ₹499.9

Book Value ₹ 155.5

Face Value 10

52W High ₹618

Dividend Yield 0.36%

52W Low ₹ 230

Edit Ratio

Titan Bio-Tech Research see more...

Overview Inc. Year: 1992Industry: Chemicals

Titan Bio-Tech Ltd is a leading biotechnology company focused on advancing scientific research and development in the field of life sciences. With a strong commitment to innovation and excellence, Titan Bio-Tech is dedicated to improving human health and quality of life through its cutting-edge biotechnological solutions. The company specializes in the discovery, development, and commercialization of novel therapeutics and diagnostics, utilizing state-of-the-art technologies and a multidisciplinary approach. Titan Bio-Tech's portfolio encompasses a wide range of areas, including pharmaceuticals, genomics, proteomics, and bioinformatics. With a team of renowned scientists and industry experts, the company is actively engaged in collaborative partnerships and strategic alliances to accelerate the translation of scientific breakthroughs into impactful healthcare solutions. Titan Bio-Tech's mission is to revolutionize the biotech landscape by bringing transformative treatments and diagnostic tools to patients worldwide.

Titan Bio-Tech Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Titan Bio-Tech Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Net Sales	42	36	33	35	42	30	37	35	43	46
Other Income	0	0	0	0	1	0	0	0	1	0
Total Income	42	37	33	35	43	31	37	35	44	46
Total Expenditure	32	28	26	27	31	26	30	27	35	35
Operating Profit	11	9	8	8	11	4	7	8	9	11
Interest	0	0	0	0	0	0	0	0	0	0
Depreciation	1	1	1	1	1	1	1	1	1	1
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	10	8	7	8	11	4	6	7	8	10
Provision for Tax	2	2	2	2	3	1	2	2	2	3
Profit After Tax	8	6	5	6	8	3	5	5	6	7
Adjustments	-1	-1	-0	2	1	1	0	1	0	-0
Profit After Adjustments	6	5	5	8	9	3	5	6	7	7
Adjusted Earnings Per Share	7.7	6.3	6	9.1	11	3.9	6	7.5	7.9	8.7

Titan Bio-Tech Profit & Loss

#(Fig in Cr.)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	40	46	53	57	65	79	142	124	144	161
Other Income	0	1	0	0	1	0	1	1	2	1
Total Income	41	46	53	58	66	80	143	124	146	162
Total Expenditure	36	42	47	50	56	66	96	92	114	127
Operating Profit	4	4	6	7	10	14	47	32	31	35
Interest	1	1	1	2	2	2	2	1	1	0
Depreciation	1	1	1	1	2	2	2	2	3	4
Exceptional Income / Expenses	0	0	0	0	0	1	-0	0	0	0
Profit Before Tax	2	3	3	4	6	10	43	29	28	31
Provision for Tax	1	1	1	1	2	3	11	7	7	9
Profit After Tax	2	2	2	3	4	8	32	22	21	23
Adjustments	0	0	0	-0	-0	-1	-1	0	4	1
Profit After Adjustments	2	2	2	3	4	7	30	22	25	25
Adjusted Earnings Per Share	2.1	2.3	2.8	3.3	4.3	8.6	36.7	26.2	30.1	30.1

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	16%	22%	20%	0%
Operating Profit CAGR	-3%	30%	35%	0%
PAT CAGR	-5%	38%	48%	0%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	107%	17%	66%	39%
ROE Average	21%	36%	29%	20%
ROCE Average	27%	41%	32%	23%

Titan Bio-Tech Balance Sheet

#(Fig in Cr.)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	20	22	23	24	32	39	69	86	110
Minority's Interest	0	1	1	1	2	2	4	0	0
Borrowings	2	4	15	18	13	12	5	1	0
Other Non-Current Liabilities	0	0	1	2	2	3	4	4	4
Total Current Liabilities	10	13	12	12	17	22	30	24	28
Total Liabilities	34	40	52	58	66	78	111	115	142
Fixed Assets	11	11	13	14	29	31	34	35	36
Other Non-Current Assets	1	5	10	14	1	1	8	9	30
Total Current Assets	21	24	30	30	36	46	69	71	75
Total Assets	34	40	52	58	66	78	111	115	142

Titan Bio-Tech Cash Flow

#(Fig in Cr.)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	2	2	4	4	1	2	2	5	7
Cash Flow from Operating Activities	-2	5	0	2	5	6	19	22	21
Cash Flow from Investing Activities	-3	-5	-8	-6	-4	-2	-5	-16	-21
Cash Flow from Financing Activities	3	2	9	0	-0	-4	-11	-4	-2
Net Cash Inflow / Outflow	-2	2	1	-3	1	-0	4	2	-2
Closing Cash & Cash Equivalent	0	4	4	1	2	2	5	7	5

Titan Bio-Tech Ratios

#	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	2.11	2.28	2.82	3.29	4.26	8.55	36.71	26.24	30.06
CEPS(Rs)	3.19	3.28	3.87	4.65	6.81	11.66	41.05	29.11	28.59
DPS(Rs)	0.75	0.75	0.75	0.75	0	1	1.5	1.5	1.8
Book NAV/Share(Rs)	26.46	27.81	29.72	31.46	38.93	47.42	83.21	104.37	133
Core EBITDA Margin(%)	9.15	7.99	10.18	11.99	13.72	16.98	32.47	25.31	20.5
EBIT Margin(%)	8.12	7.54	9.16	11.16	12.14	16.05	31.24	24.15	20.04
Pre Tax Margin(%)	5.78	5.42	6.35	7.04	8.54	13.1	30.02	23.45	19.53
PAT Margin (%)	3.85	3.62	4.14	4.58	6.03	9.87	22.29	17.55	14.6
Cash Profit Margin (%)	5.82	5.19	5.68	6.19	8.66	12.13	23.85	19.47	16.41
ROA(%)	4.87	4.81	4.73	4.85	6.32	10.89	33.5	19.16	16.37
ROE(%)	7.97	8.42	9.8	11.27	13.84	21.97	58.74	27.98	21.44
ROCE(%)	12.21	12.06	12.32	13.59	14.88	21.45	60.8	33.74	27.4
Receivable days	55.19	46.03	42.44	44.28	47.85	48.49	38.45	50.91	47.36
Inventory Days	95.26	82.32	88.2	100.62	108.86	112.82	77.64	99.29	89.79
Payable days	20.52	19.26	17.27	14.3	18.04	29.07	23.89	24.97	25.39
PER(x)	13.89	15.32	16.41	19.16	10.56	4.99	5.05	9.99	6.55
Price/Book(x)	1.11	1.26	1.56	2	1.16	0.9	2.23	2.51	1.48
Dividend Yield(%)	2.56	2.14	1.62	1.19	0	2.34	0.81	0.57	0.91
EV/Net Sales(x)	0.74	0.76	1.02	1.28	0.91	0.72	1.14	1.76	1.14
EV/Core EBITDA(x)	7.01	7.84	9.56	9.86	6.13	4.11	3.45	6.75	5.24
Net Sales Growth(%)	0	13.53	15.22	8.79	13.13	22.39	79.05	-13.14	16.55
EBIT Growth(%)	0	7.04	31.04	34.5	21.34	61.82	248.46	-32.84	-3.28
PAT Growth(%)	0	8.35	23.34	22.34	46.64	100.33	304.54	-31.61	-3.04
EPS Growth(%)	0	8.35	23.34	16.61	29.71	100.6	329.32	-28.52	14.57
Debt/Equity(x)	0.38	0.53	0.98	1.06	0.74	0.61	0.21	0.09	0.06
Current Ratio(x)	2.03	1.88	2.41	2.51	2.14	2.06	2.33	2.95	2.74
Quick Ratio(x)	0.97	1.01	1.23	1.06	0.9	0.81	1.24	1.51	1.43
Interest Cover(x)	3.47	3.57	3.26	2.71	3.37	5.43	25.72	34.22	38.69
Total Debt/Mcap(x)	0.34	0.42	0.63	0.53	0.64	0.68	0.09	0.03	0.04

Titan Bio-Tech Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	55.88	55.88	55.88	55.88	55.88	55.88	55.88	55.88	55.88	55.88
FII	0	0	0	0	0	0	0	0	0	0
DII	0	0	0	0	0	0	0	0	0	0.23
Public	44.12	44.12	44.12	44.12	44.12	44.12	44.12	44.12	44.12	43.9
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	0.46	0.46	0.46	0.46	0.46	0.46	0.46	0.46	0.46	0.46
FII	0	0	0	0	0	0	0	0	0	0
DII	0	0	0	0	0	0	0	0	0	0
Public	0.36	0.36	0.36	0.36	0.36	0.36	0.36	0.36	0.36	0.36
Others	0	0	0	0	0	0	0	0	0	0
Total	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83

Pros

Company has delivered good profit growth of 47% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 36%
Company has reduced debt.
Company is almost debt free.

Cons

Debtor days have increased from 24.97 to 25.39days.
Stock is trading at 3.2 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.